Tags

Type your tag names separated by a space and hit enter

Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion.
Oncol Rep 2015; 34(3):1503-9OR

Abstract

In the present study, in order to analyze abnormalities in DNA methylation in glioma, we utilized a large cohort methylation microarray (119 glioma samples). Genes associated with tumor grade progression were screened through Significance Analysis of Microarrays (SAM) in the methylation microarray. We found that Rab27b was hypomethylated in high-grade glioma (anaplastic gliomas and glioblastomas) compared with low-grade glioma (astrocytoma, oligodendrocytoma and oligoastrocytoma) (p=0.02). In 52 glioma samples, we determined both the methylation status of the Rab27b promoter region and protein expression, and confirmed a negative correlation between the methylation status and expression (p<0.01). Immunohistochemistry of 91 gliomas revealed that the Rab27b expression scores of high-grade glioma were higher than scores of low-grade gliomas (p<0.01). In high‑grade gliomas, patients haboring Rab27b hypomethylation or overexpression had unfavorable survival prognosis. Transwell invasion assays identified that invasive cell number of glioma U87 and LN229 cells decreased when Rab27b was knocked down. Decreased invasion partly resulted from reduced expression and activation of MMP-9 after Rab27b knockdown. Downregulation of Rab27b also suppressed tumor growth in vivo. Hypomethylated Rab27b was identified as a progression-associated and prognostic molecular marker of glioma.

Authors+Show Affiliations

Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, P.R. China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26165699

Citation

Wang, Hongjun, et al. "Hypomethylated Rab27b Is a Progression-associated Prognostic Biomarker of Glioma Regulating MMP-9 to Promote Invasion." Oncology Reports, vol. 34, no. 3, 2015, pp. 1503-9.
Wang H, Wang Y, Bao Z, et al. Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. Oncol Rep. 2015;34(3):1503-9.
Wang, H., Wang, Y., Bao, Z., Zhang, C., Liu, Y., Cai, J., & Jiang, C. (2015). Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. Oncology Reports, 34(3), pp. 1503-9. doi:10.3892/or.2015.4125.
Wang H, et al. Hypomethylated Rab27b Is a Progression-associated Prognostic Biomarker of Glioma Regulating MMP-9 to Promote Invasion. Oncol Rep. 2015;34(3):1503-9. PubMed PMID: 26165699.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. AU - Wang,Hongjun, AU - Wang,Yongzhi, AU - Bao,Zhaoshi, AU - Zhang,Chuanbao, AU - Liu,Yanwei, AU - Cai,Jinquan, AU - Jiang,Chuanlu, Y1 - 2015/07/13/ PY - 2015/04/06/received PY - 2015/06/23/accepted PY - 2015/7/14/entrez PY - 2015/7/15/pubmed PY - 2016/5/10/medline SP - 1503 EP - 9 JF - Oncology reports JO - Oncol. Rep. VL - 34 IS - 3 N2 - In the present study, in order to analyze abnormalities in DNA methylation in glioma, we utilized a large cohort methylation microarray (119 glioma samples). Genes associated with tumor grade progression were screened through Significance Analysis of Microarrays (SAM) in the methylation microarray. We found that Rab27b was hypomethylated in high-grade glioma (anaplastic gliomas and glioblastomas) compared with low-grade glioma (astrocytoma, oligodendrocytoma and oligoastrocytoma) (p=0.02). In 52 glioma samples, we determined both the methylation status of the Rab27b promoter region and protein expression, and confirmed a negative correlation between the methylation status and expression (p<0.01). Immunohistochemistry of 91 gliomas revealed that the Rab27b expression scores of high-grade glioma were higher than scores of low-grade gliomas (p<0.01). In high‑grade gliomas, patients haboring Rab27b hypomethylation or overexpression had unfavorable survival prognosis. Transwell invasion assays identified that invasive cell number of glioma U87 and LN229 cells decreased when Rab27b was knocked down. Decreased invasion partly resulted from reduced expression and activation of MMP-9 after Rab27b knockdown. Downregulation of Rab27b also suppressed tumor growth in vivo. Hypomethylated Rab27b was identified as a progression-associated and prognostic molecular marker of glioma. SN - 1791-2431 UR - https://www.unboundmedicine.com/medline/citation/26165699/Hypomethylated_Rab27b_is_a_progression_associated_prognostic_biomarker_of_glioma_regulating_MMP_9_to_promote_invasion_ L2 - http://www.spandidos-publications.com/or/34/3/1503 DB - PRIME DP - Unbound Medicine ER -